Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
- PMID: 16344336
- DOI: 10.1001/archneur.63.2.nct50002
Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
Abstract
Context: There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD).
Objective: To evaluate the effects of testosterone therapy on cognition, neuropsychiatric symptoms, and quality of life in male patients with mild AD and healthy elderly men.
Design: Twenty-four-week, randomized, double-blind, placebo-controlled, parallel-group study.
Setting: Memory disorders clinics as well as general neurology and medicine clinics from University of California medical centers at Los Angeles, San Francisco, and Irvine.
Patients or other participants: Sixteen male patients with AD and 22 healthy male control subjects. Healthy elderly control men were recruited from the community through advertisements as well as through the university-based clinics.
Intervention: Testosterone and placebo, in the form of hydroalcoholic gel (75 mg), were applied daily to the skin of the participants.
Main outcome measures: Instruments assessing cognitive functioning (Alzheimer's Disease Assessment Scale-Cognitive Subscale, California Verbal Learning Test, Block Design Subtest, Judgment of Line Orientation, Developmental Test of Visual-Motor Integration), neuropsychiatric symptoms (Neuropsychiatric Inventory), global functioning (Clinician's Interview-Based Impression of Change), and quality of life (Quality of Life-Alzheimer Disease Scale).
Results: For the patients with AD, the testosterone-treated group had significantly greater improvements in the scores on the caregiver version of the quality-of-life scale (P = .01). No significant treatment group differences were detected in the cognitive scores at end of study, although numerically greater improvement or less decline on measures of visuospatial functions was demonstrated with testosterone treatment compared with placebo. In the healthy control group, a nonsignificant trend toward greater improvement in self-rated quality of life was observed in the testosterone-treated group (P = .09) compared with placebo treatment. No difference between the treatment groups was detected in the remaining outcome measures. Testosterone treatment was well tolerated with few adverse effects relative to placebo.
Conclusions: Results suggest that testosterone replacement therapy improved overall quality of life in patients with AD. Testosterone had minimal effects on cognition.
Similar articles
-
Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.Arch Neurol. 2006 May;63(5):729-35. doi: 10.1001/archneur.63.5.729. Arch Neurol. 2006. PMID: 16682542 Clinical Trial.
-
Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial.Alzheimers Dement. 2010 Jan;6(1):1-10.e1. doi: 10.1016/j.jalz.2009.10.003. Alzheimers Dement. 2010. PMID: 20129316 Clinical Trial.
-
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.Am J Geriatr Psychiatry. 2009 Sep;17(9):752-9. doi: 10.1097/JGP.0b013e3181aad585. Am J Geriatr Psychiatry. 2009. PMID: 19700948 Clinical Trial.
-
[Duxil and cognitive deficiency in the elderly. Results of a 6-month controlled multicenter study].Ann Med Interne (Paris). 1990;141 Suppl 1:31-5. Ann Med Interne (Paris). 1990. PMID: 2082783 Review. French.
-
Late clinical testing of cognition enhancers: demonstration of efficacy.Pharmacopsychiatry. 1990 Feb;23 Suppl 2:60-2; discussion 63-4. doi: 10.1055/s-2007-1014535. Pharmacopsychiatry. 1990. PMID: 2186415 Review.
Cited by
-
Sex steroid and cognitive function among community-dwelling older men with or without vascular risk factors: a cross-sectional study.BMC Geriatr. 2024 Feb 13;24(1):147. doi: 10.1186/s12877-024-04727-6. BMC Geriatr. 2024. PMID: 38350861 Free PMC article.
-
Geroscience and Alzheimer's Disease Drug Development.J Prev Alzheimers Dis. 2023;10(4):620-632. doi: 10.14283/jpad.2023.103. J Prev Alzheimers Dis. 2023. PMID: 37874083 Free PMC article.
-
Effect of exercise on the hypothalamic-pituitary-gonadal axis in a rat model of Alzheimer's disease.Sci Rep. 2023 Aug 31;13(1):14300. doi: 10.1038/s41598-023-41415-8. Sci Rep. 2023. PMID: 37653057 Free PMC article.
-
[Testosterone and Alzheimer's disease].Probl Endokrinol (Mosk). 2022 Jun 24;68(5):97-107. doi: 10.14341/probl13136. Probl Endokrinol (Mosk). 2022. PMID: 36337024 Free PMC article. Russian.
-
Testosterone, cognitive decline and dementia in ageing men.Rev Endocr Metab Disord. 2022 Dec;23(6):1243-1257. doi: 10.1007/s11154-022-09728-7. Epub 2022 May 28. Rev Endocr Metab Disord. 2022. PMID: 35633431 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical